World Sleep Industry ENCYCLOPEDIA

Pharmacovigilance And Post-Market Surveillance

6.5.1

Definition, scope, and adjacent-service boundaries

Pharmacovigilance comprises activities for detecting, assessing, understanding, and preventing adverse reactions and other harmful problems related to medicines. Post-market surveillance continuously collects real-use information on safety, medication errors, lack of effectiveness, misuse, abuse, overdose, occupational exposure, quality defects, and special populations to update knowledge of a medicine's benefit-risk balance. It is an extended capability within WSIC 6.5.1, Clinical Trial Services. Deliverables commonly include the pharmacovigilance system and master file, individual case safety report processing, literature and regulatory surveillance, signal management, periodic safety reports, risk-management plans, post-authorisation safety studies, risk communication, effectiveness evaluation, and inspection support.

This service differs from investigational-product safety reporting during a trial, the preceding EDC service, medical information, complaint customer service, and quality release. It is also not the same as device vigilance or adverse-event regimes for cosmetics and dietary supplements. One item may trigger pharmacovigilance, quality investigation, recall, medical information, clinical research, and privacy workflows, but their assessments and reporting duties do not replace one another. A service provider supports the legally responsible party and cannot assume a regulator's authority to determine causality, approve labeling, or order action. Marketing authorization does not mean that every risk is known.

System governance, responsibility network, and sources

The marketing authorisation holder or other responsible party establishes a pharmacovigilance system covering all products, countries, and partners. It appoints a suitably empowered and competent responsible person and maintains organization charts, responsibilities, procedures, training, performance oversight, quality control, audit, deviations, and CAPA. The system master file should describe actual operation rather than serve as an inspection-only template. Licensing, co-promotion, distribution, customer care, patient-support and market-research programs, digital media, contract research organizations, and group affiliates need safety-data exchange agreements defining collection scope, day zero, transfer timelines, languages, follow-up, duplicates, submission, retention, and oversight.

Intake sources include spontaneous reports from health professionals and patients, medical information and complaints, literature, studies and registries, patient-support or market programs, partners, regulatory databases, and applicable company-controlled digital channels. Every role that may encounter safety information needs to recognize and transfer it promptly. A report cannot be rejected because causality is uncertain, details are incomplete, or the reporter uses nontechnical language. Channel inventories, business-day and after-hours coverage, translation, time zones, and downtime alternatives should be exercised. Outsourcing does not transfer ultimate responsibility; the responsible party requires access to original information, processing status, submission evidence, and quality metrics.

Case intake, medical assessment, and compliant reporting

Case processing first preserves the original report and receipt time and checks for an identifiable patient, identifiable reporter, suspect medicine, and adverse event before duplicate search, follow-up, translation, coding, and medical assessment. Seriousness is distinguished from symptom intensity, while expectedness, reportability, and causal possibility are assessed separately. The record covers narrative, chronology, indication, dose, dechallenge and rechallenge, concomitant medicines, history, tests, outcome, and lot when available. Reasonable follow-up can seek missing information, but questions should not lead the answer merely to fill fields, and contact frequency should respect patient and clinician burden.

The reporting clock begins on the initial awareness date defined by applicable rules. Serious or expedited cases receive priority triage, medical review, and submission, and meaningful new information is sent as a linked follow-up. Duplicate cases are controlled across headquarters, local holders, partners, and regulatory systems, preserving the basis for merging and every source. Medical and medicinal-product dictionaries have controlled versions and quality review. Electronic transmission requires validated format, acknowledgements, and failed-message retransmission. Case identifiers follow data-minimization, access, and masking rules while retaining the traceability required for regulation, audit, and medical evaluation.

Signal detection, prioritization, and evidence assessment

Signal management proceeds from detection, validation, and confirmation through analysis, prioritization, assessment, recommended action, closure, and continued surveillance. Every step has an owner, date, evidence, and rationale. Sources may include case clusters, medical literature, clinical and nonclinical studies, real-world data, medication errors, quality complaints, class effects, and regulatory intelligence. Priority considers seriousness, reversibility, exposure, susceptible populations, novelty, biological plausibility, preventability, public impact, and treatment alternatives rather than ranking signals only by report count. Proportionate protection can begin before a full assessment is complete when information suggests an urgent risk.

Spontaneous reports are affected by under-reporting, stimulated reporting, duplication, missing detail, confounding by indication and co-medication, and unknown exposure counts. Report totals cannot estimate incidence, and one case or a disproportionality statistic does not prove causality. Conversely, the absence of disproportionate reporting does not establish absence of risk. Assessment examines case definitions, chronology, dechallenge and rechallenge, background rates, exposure denominators, dose response, mechanism, class effects, trials, and observational studies and considers alternative explanations. Data mining generates hypotheses; conclusions require clinical judgment and evidence from multiple sources.

Periodic benefit-risk evaluation and post-authorisation studies

A periodic report is not merely a case listing. At its defined data lock point, it integrates worldwide exposure, safety signals, trials and observational studies, literature, regulatory actions, important risks, and missing information to judge whether the overall benefit-risk balance in authorized use has changed. A risk-management plan links identified risks, potential risks, and missing information to routine or additional pharmacovigilance, risk-minimization measures, milestones, and effectiveness measures. Indications, formulations, labeling, and conditions of use differ across markets. Core assessment can be coordinated, but frequency, format, and local actions require jurisdiction-specific checks.

A post-authorisation safety study begins with a specific safety question and prespecifies population, exposure, comparator, outcome, time zero, follow-up, confounding control, missingness, and analysis rather than searching for data to support a preferred conclusion. Electronic health records, claims, registries, prescribing data, or device data must be shown fit for use: key variables should be operational, accurate in the target population, and temporally interpretable, with misclassification, selection bias, and residual confounding assessed. Sleep medicines warrant particular attention to next-day impairment and driving, falls, complex sleep behaviors, respiratory risk, cognitive or psychiatric effects, tolerance, dependence, abuse, withdrawal, alcohol or sedative co-use, and older, pregnant, hepatically impaired, or renally impaired populations.

Risk control, communication, and effectiveness

A confirmed new risk can lead to revised labeling and patient information, direct professional communication, packaging or dose changes, educational tools, restricted access, added studies, lot action, supply suspension, recall, or authorization change. The response should be proportionate to magnitude, uncertainty, preventability, and therapeutic value and identify responsibility, effective date, target audience, and escalation criteria. An adverse event involving a quality defect also enters the quality system and lot traceability, but an unfinished quality investigation must not delay participant protection or mandatory safety reporting.

Safety communication should be timely, accurate, balanced, and actionable. It describes known facts, uncertainty, affected products and populations, actions for patients and professionals, urgent symptoms, alternatives, and where updates will appear. Vague advice to use caution is not a substitute for a concrete action, while presenting an unvalidated signal as proven causation can cause harm and panic. Effectiveness evaluation separates delivery, changes in knowledge and behavior, and changes in serious outcomes or medication errors. Prescription volume or distribution counts alone do not show that risk is controlled; inadequate performance should prompt revision.

System quality, continuity, and claim boundaries

Safety databases and interfaces are validated for intended use and maintain unique case identifiers, versions, audit trails, role permissions, blinding, dictionaries, electronic submissions, and record retention. Trial, medical-information, complaint, quality, literature, and partner databases are reconciled periodically to prevent missed transfer and duplicate submission. Operational metrics cover intake and submission timeliness, follow-up, duplicates, coding, quality review, signal backlogs, periodic reports, training, and CAPA and are interpreted by criticality. A target of perfect timeliness must not encourage premature closure of incomplete cases or concealment of late reports.

Continuity planning covers staff deputies, system downtime, regulatory gateway failure, cyberattack, disaster, and vendor exit and tests restoration, temporary intake, preservation of reporting clocks, retransmission, and reconciliation. Audit and inspection should trace original information through assessment, decision, submission, and risk action, with findings entering root-cause and effectiveness review. Pharmacovigilance cannot establish that a medicine is absolutely safe or promise no adverse reactions, no signals, or no regulatory action. Reports in public databases are not a basis for comparing treatments. Credible service protects patients through transparent uncertainty, timely escalation, traceable judgment, and continuous learning.